Analytical comparison of natural and pharmaceutical ventricular myosin activators
about
In vivo myosin step-size from zebrafish skeletal muscleTargeting the sarcomere to correct muscle functionN-Terminus of Cardiac Myosin Essential Light Chain Modulates Myosin Step-Size.Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels.The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the ratMolecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-CIn vitro and in vivo single myosin step-sizes in striated muscleStructural basis for drug-induced allosteric changes to human β-cardiac myosin motor activityHypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice.The myosin activator omecamtiv mecarbil: a promising new inotropic agent.In vitro actin motility velocity varies linearly with the number of myosin impellers.Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke.The role of super-relaxed myosin in skeletal and cardiac muscleOmecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle.Single cardiac ventricular myosins are autonomous motors.Do Actomyosin Single-Molecule Mechanics Data Predict Mechanics of Contracting Muscle?
P2860
Q27336210-36563A25-5EFE-4330-BD98-703C31B3940AQ28260629-1AEA027B-D1D6-4AC0-8B26-BEA5C2B86A3FQ30701531-8228B531-3793-4E6C-A7D6-4397F58C55FFQ34549974-7184C6A1-5831-4B9B-80DB-B7AD73CE04A8Q36036237-5C4FE092-DD0B-40E6-A71A-CBF0C13AFFFFQ36341946-5464B968-ACF5-4444-BC32-7C2D5238E7BDQ36609420-2FB30F89-7195-4D65-ABED-A1AFA9C3BB56Q37031923-25AB9E95-5756-44B0-B613-3B6CA5CC34A3Q38735729-995347CF-F737-4599-A8A7-C095BCE9B81BQ38870685-BA30BDBB-9FB2-4F48-B22E-20575656B83FQ38993661-BA6033B7-2EE4-44A6-94D2-8FD3599E08D6Q41814795-10178CD8-D106-4928-895E-B8B88689A57CQ42278153-7D791029-30ED-4EEA-9553-0804FEFB2CF6Q48049889-9F8ABC83-39FC-43C5-9D1D-25718C4765BEQ52579753-788FF7B2-DFFA-482E-906B-CA0D5A1CD6BDQ56887897-96C0F739-000C-4D5D-981C-0ED9D5DA604E
P2860
Analytical comparison of natural and pharmaceutical ventricular myosin activators
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@ast
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@en
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@nl
type
label
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@ast
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@en
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@nl
prefLabel
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@ast
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@en
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@nl
P2093
P2860
P356
P1433
P1476
Analytical comparison of natural and pharmaceutical ventricular myosin activators
@en
P2093
Katalin Ajtai
Thomas P Burghardt
Yihua Wang
P2860
P304
P356
10.1021/BI500730T
P407
P577
2014-08-07T00:00:00Z